Meiji Seika Pharma Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meiji Seika Pharma Co., Ltd
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Chemo-Sero Therapeutic Research Institute of Japan
- Meiji Holdings
- Meiji Seika Kaisha
- KM Biologics Co., Ltd.
- Romeck Pharma, LLC
- Meiji Pharma USA Inc.